- Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial
[作者：Armitage, J; Bowman, L; Wallendszus, K; Bulbulia, R; Rahimi, K; Haynes, R; Parish, S; Peto, R; Collins, R; Meade, T; Sleight, P; Collins, R; Armitage, J; Bowman, L; Parish, S; Peto, R; Barton, J; Bray, C; Wincott, E; Dayanandan, R; Clarke, R; Graham, I; Simpson, D; Warlow, C; Wilken, D; Tobert, J; Mushner, T; Doll, R; Wilhelmsen, L; Fox, K; Hill, C; Sandercock, P; Webster, J; Henderson, J; Nixon, A; Lackie, S; Thompson, J; Brown, M; Blackwood, S; Morgan, M; Rhoden, W; Saeed, B; Houghton, M; Nicholson, A; Simpson, C; Hoburn, B; Cooper, I; Gallivan, A; Pickerell, E; Hancock, J; Watkinson, J; Ryder, B; Jones, S; Burbridge, W; Kitchen, M; Leary, HO; Verow, C; Meynell, L; Rollinson, L; Bain, S; Jones, A; Jewkes, C; Russon, C; Bateson, M; Gill, P; Nicol, J; Bayly, G; Stansbie, D; Andrews, G; Halestrap, M; Meredith, J; Best, R; Appleyard, D; Briggs, R; Wareing, H; Holmes, K; Holt, J; Kenyon, M; White, C; Khalifa, M; Newton, D; Wass, A; Watkinson, R; Creamer, J; Anderson, S; Bethell, A; Butler,期刊：Lancet, 页码：1658-1669 , 文章类型： Article，,卷期：2010年376-9753]
- Background Lowering of LDL cholesterol reduces major vascular events, but whether more intensive therapy safely produces extra benefits is uncertain We aimed to establish efficacy and safety of more intensive statin trea...
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
[作者：Baigent, C; Blackwell, L; Emberson, J; Holland, LE; Reith, C; Bhala, N; Peto, R; Barnes, EH; Keech, A; Simes, J; Collins, R,期刊：Lancet, 页码：1670-1681 , 文章类型： Article，,卷期：2010年376-9753]
- Background Lowering of LDL cholesterol with standard statin regimens reduces the risk of occlusive vascular events in a wide range of individuals We aimed to assess the safety and efficacy of more intensive lowering of L...
- Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial
[作者：Dondorp, AM; Fanello, CI; Hendriksen, ICE; Gomes, E; Seni, A; Chhaganlal, KD; Bojang, K; Olaosebikan, R; Anunobi, N; Maitland, K; Kivaya, E; Agbenyega, T; Nguah, SB; Evans, J; Gesase, S; Kahabuka, C; Mtove, G; Nadjm, B; Deen, J; Amumpaire, JM; Nansumba, M; Karema, C; Umulisa, N; Uwimana, A; Mokuolu, OA; Adedoyin, OT; Johnson, WBR; Tshefu, AK; Onyamboko, MA; Sakulthaew, T; Ngum, WP; Silamut, K; Stepniewska, K; Woodrow, CJ; Bethell, D; Wills, B; Oneko, M; Peto, TE; von Seidlein, L; Day, NPJ; White, NJ,期刊：Lancet, 页码：1647-1657 , 文章类型： Article，,卷期：2010年376-9753]
- Background Severe malaria is a major cause of childhood death and often the main reason for paediatric hospital admission in sub Saharan Africa Quinine is still the established treatment of choice, although evidence from...
|